Although each CAd component (oncolysis, PD-L1 blocking antibody or IL-12) provided some level of tumor control in both CAd-treated and untreated tumors when combined with HER2.CART, none eliminated the CAd-treated tumor. This evidence concerns the gene ERBB2 and neoplasm.